

26 September 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Investor Event and Presentation

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that the Company will be presenting at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Brewery Place, Leeds, LS10 1NE. Event registration opens at 4.30 pm and presentations commence at 5.00 pm.

Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial Officer, will deliver a presentation, offering investors the opportunity to engage directly with the Company and gain valuable insights into its recent progress.

For further information on the ShareSoc Growth Company Seminar and registration, please visit the event website: <https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/>

A link to Aptamer's presentation will be made available on the Company website following the event.

No new material information will be disclosed at this event.

- Ends -

For further information, please contact:

Aptamer Group plc	+44 (0) 1904 217 404
Dr Arron Tolley, Chief Executive Officer	
SPARK Advisory Partners Limited - Nominated Adviser	+44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat	
Turner Pope Investments (TPI) Limited - Broker	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	
Northstar Communications Limited - Investor Relations	+44 (0) 113 730 3896
Sarah Hollins	

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US 210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPPUUABUPAGQA